In this study, FSCN1 was regarded as an RBP and a breakthrough point to explore the possible role of FSCN1 in gene transcription and alternative splicing (AS), thereby providing insight into the future diagnosis and treatment of NSCLC. This evidence concerns the gene FSCN1 and non-small cell lung carcinoma.